Authors have reported conflicting results on the persistence of hepatitis C virus (HCV) infection in patients having sustained virologic response (SVR) to treatment. Therefore, we sought to determine whether chemotherapy leads to viral relapse in 30 HCV-infected patients who had SVR before cancer diagnosis. Half of them had hematologic malignancies. Most (60%) received HCV therapy with interfer...

conclusions examination of the fasting lipid profile has clinical importance in predicting the efficacy of peg-ifn-α-2b plus rbv combination therapy for patients with hcv g1b even after the discovery of the il28 genotype as a potent predictive factor. objectives to re-examine the significance of lipoprotein profiles on virological response to peg-ifn plus rbv combination therapy in patients wit...

patients and methods this cross - sectional study was conducted on 143 thalassemic patients with chronic hepatitis c, who were treated with a combination of peg-ifn and rbv regimen. the rs12979860 and rs8099917 polymorphisms were assessed as the most common polymorphisms near the il28b gene by the polymerase chain reaction-restriction fragment length polymorphism (pcr-rflp) method. objectives w...

A Sustained virologic response is durable in patients with chronic hepatitis C with peginterferon alfa-2a and ribavirin. The current standard therapy for chronic hepatitis C virus (HCV) infection is the combination of pegylated interferon and ribavirin. The ultimate goal of treatment in patients with chronic HCV infection is to completely eradicate HCV in infected hosts, and prevent liver-relat...

context there is growing evidence that interferon lambda 4 (ifnl4) polymorphism is related to sustained virological response (svr) in hepatitis c virus (hcv) infection. we analyzed the relationship between ifnl4 (rs368234815) polymorphism and svr in dual- and triple- therapy in hcv genotype 1, 2, 3 and 4 infected asian, caucasian and african patients. conclusions favorable ifnl4 rs368234815 gen...

Pegylated-interferon plus ribavirin is the standard treatment for chronic hepatitis C. Sustained virological response (SVR) rates of up to 80% are reported in genotype 2 and 3 chronic hepatitis C cases. Obesity, a modifiable risk factor, may have a deleterious effect on antiviral treatment. We performed this study to examine the efficacy and safety of pegylated-interferon and ribavirin therapy ...

BACKGROUND AND STUDY AIMS Large international clinical trials conducted in the past 5 years rapidly improved the treatment of chronic hepatitis C; however, it is unclear whether the advances seen in clinical trials are being paralleled by similar improvements in routine clinical practice. PegIntrust is a Belgian community-based trial evaluating the sustained virological response. PATIENTS AND...

UNLABELLED Hepatitis C virus genotype 4 (HCV-4) is the most common variant of the hepatitis C virus (HCV) in the Middle East and Africa, particularly Egypt. This region has the highest prevelance of HCV worldwide, with more than 90% of infections due to genotype 4. HCV-4 has recently spread in several Western countries, particularly in Europe, due to variations in population structure, immigrat...

BACKGROUND Interferon-α in combination with ribavirin is the current gold standard for treatment of chronic hepatitis C. It is unknown if the development of autoimmune thyroid disease (TD) during treatment confers an improved chance of achieving sustained virologic response. The aim of this study is to assess the chance of achieving sustained virologic response (SVR) in patients who developed T...